1Stevens DA. Therapy for opportunistic fungal infectious: past,present and future[ J ]. Indian J Cancer, 1995,32 (1) : 1.
2Powderly WG,Keath M, Anderson S, et al. Amphotericin B-resistant Cyptococcus neoformans in a patient with AIDS[J]. Infect Dis Clin Pract , 1990,1 : 314.
3Louie A,Kaw P,Banerjee P, et al. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endoearditis and pyelonephritis [ J ]. Anti Agents Chem ,2001,45(2) :485.
4Yamaguchi H. Molecular and biochemical mechanisms of drug resistance in fungi [ J ]. Nippon Ishinkin Gakkai Zasshi, 1999,40(4) : 199.
5Kohli A,Smriti,Mukhopadhyay K, et al. In vitro low-level resistance to azoles in Candida albicans is associated with changes in membrane lipid fluidity and asymmetry[J]. Anti Agents Chem,2002,46(4): 1046.
6Loftier J, Einsele H, Hebart H, et al. Phospholipid and sterol analysis of plasma membranes of azole-resistant Candida albicans strains[J]. FEMS Microbiol Lett ,2000,185(1) :59.
7Perea S, Lopez-Robit JL, Kirkpatrick WR, et al. Prevalence of molecular mechanimns of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from HIV-infected patients [ J ]. Anti Agents Chem. 2001.45 (10) : 2676.
8Asai K, Tsuchimori N, Okonogi K, et al. Formation of azole-resistant Candida albicans by mutation of sterol 14-demethylase P450[J]. Anti Agents Chem, 1999,43(5) : 1163.
9Edlind TD,Henry KW, Metera KA, et al. Aspergillus fumigatus CYP51 sequence: potential basis for fluconazole resistance[J]. Med Myco1, 2001, 39 ( 3 ) :299.
10Sanglard D, Ischer F, Koymans L, et al. Amino acid substitutions in the cytochrome P-450 lanosterol 14α-demethylase(CYP51A1 )from azole-resistant Candida albicans clinical isohtes contribute to resistance to azole antifungal agents [ J ]. Anti Agents and Chemo ,1998,42(2) :241.
